依普奈珠单抗治疗慢性偏头痛的疗效与安全性:PROMISE-2研究
PROMISE-2为3期随机双盲安慰剂对照研究,纳入1072例慢性偏头痛成人患者,比较静脉依普奈珠单抗100mg、300mg与安慰剂(第0天和第12周给药)的疗效。主要终点为第1至12周每月偏头痛天数(MMD)较基线的变化。结果显示100mg和300mg均显著优于安慰剂,耐受性良好,提供I级证据。
要点
- 依普奈珠单抗100mg和300mg均显著减少慢性偏头痛患者每月偏头痛天数。
- 治疗中出现的不良事件发生率与安慰剂相当,鼻咽炎为唯一略高于安慰剂的常见不良事件。
- 单次静脉给药后疗效可持续至第12周,支持其用于慢性偏头痛的预防治疗。
核心结论
- 在慢性偏头痛患者中,依普奈珠单抗100mg和300mg可显著减少每月偏头痛天数,且耐受性良好,安全性可接受。
研究设计与样本
- PROMISE-2为3期、多中心、随机、双盲、安慰剂对照、平行组研究,纳入1072例慢性偏头痛成人患者,随机接受静脉依普奈珠单抗100mg、300mg或安慰剂,第0天和第12周给药。
主要发现
- 第1至12周每月偏头痛天数较基线变化:安慰剂-5.6天,100mg组-7.7天(p<0.0001 vs 安慰剂),300mg组-8.2天(p<0.0001 vs 安慰剂)。
- 治疗中出现的不良事件发生率:100mg组43.5%,300mg组52.0%,安慰剂组46.7%。
- 鼻咽炎是唯一在依普奈珠单抗治疗患者中发生率超过安慰剂2%以上的不良事件,仅见于300mg组(依普奈珠单抗9.4% vs 安慰剂6.0%)。
关键数值与推荐
- 主要终点为第1至12周每月偏头痛天数(MMD)较基线的变化。
- 基线平均MMD在各组约为16.1天。
- 研究提供I级证据:单次剂量依普奈珠单抗可在12周治疗期内减少MMD。
临床怎么用
- 对于慢性偏头痛患者,可考虑静脉使用依普奈珠单抗100mg或300mg进行预防性治疗,每12周给药一次。
- 治疗前应评估患者偏头痛频率,治疗后关注每月偏头痛天数变化及鼻咽炎等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). METHODS: The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12. RESULTS: Among treated participants (n = 1,072), baseline mean number of MMDs was ≈16.1 across groups. Treatment with eptinezumab 100 and 300 mg was associated with significant reductions in MMDs across weeks 1 to 12 compared with placebo (placebo -5.6, 100 mg -7.7, p < 0.0001 vs placebo; 300 mg -8.2, p < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab-treated patients at an incidence of >2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). CONCLUSION: In patients with CM, eptinezumab 100 and 300 mg was associated with a significant reduction in MMDs from the day after IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that for patients with CM, a single dose of eptinezumab reduces MMDs over 12 weeks of treatment. CLINICALTRIALSGOV IDENTIFIER: NCT02974153.
引用
- Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020. PMID: 32209650. doi:10.1212/WNL.0000000000009169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。